CN116751849A - LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用 - Google Patents
LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用 Download PDFInfo
- Publication number
- CN116751849A CN116751849A CN202310587248.1A CN202310587248A CN116751849A CN 116751849 A CN116751849 A CN 116751849A CN 202310587248 A CN202310587248 A CN 202310587248A CN 116751849 A CN116751849 A CN 116751849A
- Authority
- CN
- China
- Prior art keywords
- lncrna
- aortic dissection
- product
- diagnosing
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002251 Dissecting Aneurysm Diseases 0.000 title claims abstract description 49
- 206010002895 aortic dissection Diseases 0.000 title claims abstract description 48
- 108091046869 Telomeric non-coding RNA Proteins 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims description 10
- 239000002773 nucleotide Substances 0.000 claims abstract description 3
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 7
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
Abstract
本发明提供了LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，所述LncRNA MSTRG16457.2的核苷酸序列如SEQ ID NO:1所示，所述产品通过检测LncRNA MSTRG16457.2的表达水平诊断主动脉夹层。本发明通过构建大鼠主动脉夹层模型，在主动脉夹层模型的LncRNA中筛选发现了LncRNA MSTRG16457.2的新用途，并进一步研究了LncRNA MSTRG16457.2表达对主动脉夹层的影响，为主动脉夹层的快速诊断和治疗提供了新的可行性方案。
Description
技术领域
本发明属于生物医药技术领域，涉及LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用。
背景技术
主动脉夹层(aortic dissection，AD)指主动脉腔内的血液通过主动脉内膜的破口进入主动脉壁中膜而形成的血肿，并沿主动脉长轴方向扩展，造成主动脉真假两腔分离的一种病理改变，因通常呈继发瘤样改变，过去此种情况被称为主动脉夹层动脉瘤(aorticdissecting aneurysm)，现多改称为主动脉夹层血肿(aortic dissectin ghematoma)，或主动脉夹层分离，简称主动脉夹层。
主动脉夹层临床特点为急性起病，突发剧烈疼痛、休克和血肿压迫相应的主动脉分支血管时出现的脏器缺血症状。主动脉夹层是心血管疾病的灾难性危重急症，如不及时诊治，48小时内死亡率可高达50％，故早期诊断和治疗非常必要。
发明内容
本发明的目的在于提供LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，为临床上快速诊断和治疗主动脉夹层提供一种新的可行性方案。
为实现上述目的，本发明采用的技术方案为：
LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，所述LncRNA MSTRG16457.2的核苷酸序列如SEQ ID NO:1所示。
优选地，所述产品通过检测LncRNA MSTRG16457.2的表达水平诊断主动脉夹层。
更优选地，诊断主动脉夹层的产品包括试剂或试剂盒。
更优选地，LncRNA MSTRG16457.2在主动脉夹层的生物学样品中的表达水平升高。
优选地，所述产品通过干扰LncRNA MSTRG16457.2的表达水平抑制主动脉夹层的形成。
更优选地，治疗主动脉夹层的产品包括表达LncRNA MSTRG16457.2的腺病毒载体。
本发明的有益效果在于：
本发明通过构建大鼠主动脉夹层模型，在主动脉夹层模型的LncRNA中筛选发现了LncRNA MSTRG16457.2的新用途，并进一步研究了LncRNA MSTRG16457.2表达对主动脉夹层的影响，为主动脉夹层的快速诊断和治疗提供了新的可行性方案。
附图说明
图1为3个LncRNA的PCR检测结果。
图2为本发明造模过程中的部分照片。
图3为qPCR检测各组大鼠主动脉组织中MSTRG16457.2表达情况(*P＜0.05VSControl)。
图4为载体pAdEasy-U6-CMV-EGFP的图谱。
图5为PCR检测各组中LncRNA MSTRG16457.2的表达水平。*p<0.05，与对照组相比。
图6为HE和MASSON染色观察主动脉夹层的病理情况。
具体实施方式
为了更清楚地说明本发明，下面结合实施例并对照附图对本发明作进一步详细说明。本领域技术人员应当理解，下面所具体描述的内容是说明性的而非限制性的，不应以此限制本发明的保护范围。
实施例
本发明实现的主要流程包括：
一、LncRNA MSTRG16457.2的筛选
根据高通量分析结果筛选出3个LncRNA：MSTRG7090.4(SEQ ID NO:3)、MSTRG16456.1(SEQ ID NO:2)和MSTRG16457.2(SEQ ID NO:1)，如图1所示(图中1，2，3对应SD大鼠的编号)，PCR结果显示与对照组(Control)相比，模型组(Model)中MSTRG16457.2的表达水平均显著上升，差异具有统计学意义；因此选择LncRNA MSTRG16457.2进行研究。
二、LncRNA MSTRG16457.2在主动脉夹层的表达情况
1.动物材料
30只SD大鼠，雄性，3周龄，SPF级，购于湖南斯莱克景达实验动物有限公司，许可证号SCXK(湘)2019-0004
2.试剂：β-氨基丙腈(批号：C12511686，厂家：上海麦克林生化科技有限公司)、血管紧张素Ⅱ(批号：4474-91-3，厂家：上海源叶生物科技有限公司)
3.实验过程：
饮用水中添加β-氨基丙腈(0.12％)，后续每三天额外增加0.02％氨基丙腈和每天每只两次颈部皮下注射血管紧张素(0.4mg/ml)0.3ml，持续21天。
qPCR检测各组大鼠主动脉组织中MSTRG16457.2表达情况，结果见图3，PCR结果显示与对照组(Control)相比，模型组(Model)中MSTRG16457.2的表达水平均显著上升，差异具有统计学意义。
以上实验结果表明，检测LncRNA MSTRG16457.2的表达水平的试剂或试剂盒可用于诊断主动脉夹层，LncRNA MSTRG16457.2在主动脉夹层的生物学样品中的表达水平升高。三、LncRNA MSTRG16457.2腺病毒载体构建和病毒包装
(一)腺病毒载体的制备
主要流程：
1.选择载体pAdEasy-U6-CMV-EGFP，载体图谱如图4所示，并进行设计目的片段PCR引物；
扩增条件：
2.根据如下表中顺序依次加入每种试剂，轻轻吸打混匀，置于37℃水浴锅中反应1-2h；酶切结束之后进行琼脂糖凝胶电泳，回收目的片段；
载体酶切体系如下：
3.干扰片段与载体连接：
连接反应体系(20μL)如下：
以上连接液在22℃连接1-2h，或者16℃连接过夜。
4.转化感受态DH5a或者stbl3，菌液涂板，培养12-16h；
5.挑选单克隆行进菌落验证；
6.选择菌落验证正确的阳性克隆进行测序；
7.测序正确的克隆样品进行质粒抽提。
(二)腺病毒包装
实验流程：
采用Adeasy腺病毒系统进行病毒包装过程。质粒载体进行高纯度无内毒素抽提后，采用LipofiterTM转染试剂将质粒转染293A细胞。需要说明的是，腺病毒载体构建和病毒包装流程为本领域较为成熟的技术，可通过常规技术操作实现，在此不做具体描述。
四、LncRNA MSTRG16457.2对主动脉夹层的影响
饮用水中添加β-氨基丙腈(0.12％)，后续每三天额外增加0.02％氨基丙腈和每天每只两次颈部皮下注射血管紧张素(0.4mg/ml)0.3ml。总共作用21天。作为AD组。
腺病毒干预：尾静脉注射腺病毒10μl。以不作任何处理的正常大鼠作为对照组(Control)。
取样：造模结束后第4天，处死各组大鼠。
PCR检测各组中LncRNA MSTRG16457.2的表达水平，结果如图5所示，与对照组(Control)和空载组(NC)相比，干扰组中LncRNA MSTRG16457.2的表达水平显著下降，差异具有统计学意义(P<0.05)。
病理观察结果见图6，结果显示，对照组动脉结构正常，中内膜结构完整，Masson染色可看出弹力纤维及肌层完好无破裂。模型组可见内皮损伤撕裂，且血管壁中形成假腔，弹力纤维断裂甚至消失，肌层破坏严重，胶原纤维增生，血管弹性降低。干扰LncRNAMSTRG16457.2会得到改善，说明干扰LncRNA MSTRG16457.2表达能够显著抑制主动脉夹层的形成。
以上实验结果表明，可通过干扰LncRNA MSTRG16457.2的表达水平抑制主动脉夹层的形成从而达到治疗主动脉夹层的目的。
显然，本发明的上述实施例仅仅是为更清楚地说明本发明所作的举例，而并非是对本发明的实施方式的限定，对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其他不同形式的变化或变动，这里无法对所有的实施方法予以穷举，凡是属于本发明的技术方案所引申出的显而易见的变化或变动仍处于本发明的保护范围之列。
Claims (6)
1.LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，所述LncRNAMSTRG16457.2的核苷酸序列如SEQ ID NO:1所示。
2.根据权利要求1所述的LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，其特征在于，所述产品通过检测LncRNA MSTRG16457.2的表达水平诊断主动脉夹层。
3.根据权利要求2所述的LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，其特征在于，诊断主动脉夹层的产品包括试剂或试剂盒。
4.根据权利要求2或3所述的LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，其特征在于，LncRNA MSTRG16457.2在主动脉夹层的生物学样品中的表达水平升高。
5.根据权利要求1所述的LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，其特征在于，所述产品通过干扰LncRNA MSTRG16457.2的表达水平抑制主动脉夹层的形成。
6.根据权利要求5所述的LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用，其特征在于，治疗主动脉夹层的产品包括表达LncRNA MSTRG16457.2的腺病毒载体。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310587248.1A CN116751849A (zh) | 2023-05-24 | 2023-05-24 | LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310587248.1A CN116751849A (zh) | 2023-05-24 | 2023-05-24 | LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116751849A true CN116751849A (zh) | 2023-09-15 |
Family
ID=87946866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310587248.1A Pending CN116751849A (zh) | 2023-05-24 | 2023-05-24 | LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116751849A (zh) |
-
2023
- 2023-05-24 CN CN202310587248.1A patent/CN116751849A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114807142B (zh) | 一种环状RNA-circ-Magi1及其应用 | |
| CN111286536A (zh) | 一种用于诊断心肌梗死的基因标志物及其应用 | |
| Sun et al. | Influence of MiR-154 on myocardial apoptosis in rats with acute myocardial infarction through Wnt/β-catenin signaling pathway. | |
| CN116751849A (zh) | LncRNA MSTRG16457.2在制备诊断或治疗主动脉夹层的产品中的应用 | |
| CN102242080A (zh) | miR-24用于治疗或诊断心衰或患心衰倾向或者改善心肌细胞功能的方法 | |
| CN110592207B (zh) | 一种外泌体microRNA的应用及制备的试剂盒 | |
| CN107177673A (zh) | 腹动脉瘤诊治相关基因 | |
| CN108866181B (zh) | Mboat1基因在子痫前期中的应用 | |
| CN109097358B (zh) | 一种lncRNA在预防或治疗高血压中的应用 | |
| CN108619516B (zh) | Her2-565核酸片段及her2-20kd肽段的抑制剂在制备抗肿瘤药物中的应用 | |
| CN113528528B (zh) | 一种促进耐伊马替尼慢性髓细胞白血病细胞K562/G01凋亡shRNA及其应用 | |
| CN111118143B (zh) | 检测及靶向rp11-754b17.1的试剂及其在关节炎中的应用 | |
| Vijayasarathy et al. | Identification of a stable RNA encoded by the H-strand of the mouse mitochondrial D-loop region and a conserved sequence motif immediately upstream of its polyadenylation site | |
| CN111254200B (zh) | Gal3st3基因的新用途 | |
| CN105316417B (zh) | Znrd1基因及其表达产物作为颅内动脉瘤的诊治靶标 | |
| CN110279706A (zh) | hnRNPC基因C1和/或C2亚型作为药物靶标在筛选抗癌药物中的应用 | |
| CN114736956B (zh) | piRNA作为诊断标志物在法医鉴定急性心梗和/或推断急性心梗持续发病时间中的应用 | |
| CN115961025B (zh) | 一种环状rna在制备与心肌肥厚相关的产品中的应用 | |
| CN110433170B (zh) | 心脏抽吸液miR-28-5p在心脏疾病中的应用 | |
| CN115837081A (zh) | 一种环状rna分子在制备治疗肌肉损伤的药物中的应用 | |
| CN111097039B (zh) | Ras相关蛋白2的制药用途 | |
| CN116004814A (zh) | miR-3154及其下游靶基因Pax7在VSMCs表型转化相关疾病中的医药用途 | |
| CN116059366A (zh) | 一种搭载p16-siRNA的纳米药物的构建及其在治疗梗死后心室重塑中的应用 | |
| CN111850109A (zh) | miR-122-5p作为肾纤维化无创诊断标志中及检测试剂盒 | |
| CN117653709A (zh) | 一种新型肽upcp在器官纤维化治疗中的作用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |